Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316963 · ClinicalTrials.gov registry record · Early Phase 1
Neostigmine For Snoring During DISE
A Early Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03316963 is a Early Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants.
The verdict
NCT03316963, a Early Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The study team is seeking a novel treatment for snoring involving local application of a nerve stimulant medication, neostigmine. In this study, neostigmine will be injected into 5 sites of the soft palate during a standard procedure, drug-induced sleep endoscopy, to evaluate the effect on snoring.
Interventions
- DRUG Neostigmine Methylsulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2019-03-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03316963
The ClinicalTrials.gov registry entry for NCT03316963 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neostigmine Methylsulfate is the first listed.
NCT03316963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03316963 about?
NCT03316963 is a clinical study titled "Neostigmine For Snoring During DISE". The study team is seeking a novel treatment for snoring involving local application of a nerve stimulant medication, neostigmine. In this study, neostigmine will be injected into 5 sites of the soft palate during a standard procedure, drug-induced sleep endoscopy, to evaluate the effect on snoring.
What is the current status of trial NCT03316963?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2017-11-14. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03316963?
The interventions under investigation include: Neostigmine Methylsulfate (DRUG).
Who is sponsoring clinical trial NCT03316963?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.